Abstract: The invention provides cryogels whose porosity, pore size, pore connectivity, swelling agent concentration, and/or specific volume undergoes a change from a first value to a second value in response to an electrical stimulus. The cryogels have interconnected macropores which greatly enhance their ability to rapidly undergo volumetric collapse when subjected to moderate electric fields. The cryogels of the invention can be easily integrated into arrays capable of rapid configurational and chromatic optical modulations, and when loaded with drugs, are able to coordinate the delivery profile of multiple drugs. The cryogel can be prepared by polymerizing an aqueous solution of charged monomers and cross-linker monomers at a temperature below the freezing temperature of the solvent.

Abstract: The invention provides cryogels whose porosity, pore size, pore connectivity, swelling agent concentration, and/or specific volume undergoes a change from a first value to a second value in response to an electrical stimulus. The cryogels have interconnected macropores which greatly enhance their ability to rapidly undergo volumetric collapse when subjected to moderate electric fields. The cryogels of the invention can be easily integrated into arrays capable of rapid configurational and chromatic optical modulations, and when loaded with drugs, are able to coordinate the delivery profile of multiple drugs. The cryogel can be prepared by polymerizing an aqueous solution of charged monomers and cross-linker monomers at a temperature below the freezing temperature of the solvent.

Abstract: The various embodiments provide a composition that provides local control over inflammation. The composition localizes the activities of the cytokine-neutralizing antibodies to the site of inflammation through covalent attachment to hydrophilic matrices. The various embodiments including a hydrophilic polymer, a ligand binding moiety covalently attached to the polymer, and optionally, a cellular adhesion peptide covalently attached to the polymer. The hydrophilic polymer may be a glycosaminoglycan such as hyaluronan. The cellular adhesion peptide may be linear RGD peptide sequence covalently attached to the polymer. The ligand binding moiety may be a monoclonal antibody covalently attached to the polymer. The antibody may be selected from the group consisting of an anti-IL-1?, an anti-IL-6, an anti-TNF-?, and combinations thereof. The polymer functions as a substrate or matrix for cell migration and tissue regeneration.

Abstract: The various embodiments provide a composition that provides local control over inflammation. The composition localizes the activities of the cytokine-neutralizing antibodies to the site of inflammation through covalent attachment to hydrophilic matrices. The various embodiments including a hydrophilic polymer, a ligand binding moiety covalently attached to the polymer, and optionally, a cellular adhesion peptide covalently attached to the polymer. The hydrophilic polymer may be a glycosaminoglycan such as hyaluronan. The cellular adhesion peptide may be a linear RGD peptide sequence covalently attached to the polymer. The ligand binding moiety may be a monoclonal antibody covalently attached to the polymer. The antibody may be selected from the group consisting of an anti-IL-1?, an anti-IL-6, an anti-TNF-?, and combinations thereof. The polymer functions as a substrate or matrix for cell migration and tissue regeneration.

Abstract: The various embodiments provide a composition that provides local control over inflammation. The composition localizes the activities of the cytokine-neutralizing antibodies to the site of inflammation through covalent attachment to hydrophilic matrices. The various embodiments including a hydrophilic polymer, a ligand binding moiety covalently attached to the polymer, and optionally, a cellular adhesion peptide covalently attached to the polymer. The hydrophilic polymer may be a glycosaminoglycan such as hyaluronan. The cellular adhesion peptide may be a linear RGD peptide sequence covalently attached to the polymer. The ligand binding moiety may be a monoclonal antibody covalently attached to the polymer. The antibody may be selected from the group consisting of an anti-IL-1?, an anti-IL-6, an anti-TNF-?, and combinations thereof. The polymer functions as a substrate or matrix for cell migration and tissue regeneration.